Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 18/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651365 | 0.82 | ADORA2A (0.32) | — | |
| SCHEMBL5930259 | 0.75 | HSP90AB1 (0.45) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL5578416 | 0.74 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL2054791 | 0.73 | HSP90AB1 (0.52) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL27854926 | 0.72 | CDK1 (0.71) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL9563423 | 0.71 | HSP90AB1 (0.50) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL9563426 | 0.71 | HSP90AB1 (0.50) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL10363003 | 0.71 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL10509936 | 0.70 | AHCY (0.57) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL10509931 | 0.70 | AHCY (0.57) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1068209-B1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR | NOVARTIS INT PHARM LTD (BM) | 2005-09-14 | — | — | EP | disclosed |
| US-6806375-B2 | SUCH AS FAMCICLOVIR AND PENCICLOVIR; REACTING A 2-AMINOPURINE WITH A 1,1-BIS(OXYMETHYL)-1-VINYLMETHYL CARBONATE, ESTER OR PHOSPHATE IN THE PRESENCE OF A PALLADIUM(0) CATALYST | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-10-19 | — | — | US | disclosed |
| EP-1068210-B1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES | NOVARTIS INT PHARM LTD (BM) | 2004-06-02 | — | — | EP | disclosed |
| US-20030130512-A1 | Process for the production of purine derivatives and intermediates therefor | DPT LABORATORIES, LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6555685-B1 | Preparing purine derivatives, such as famiciclovir and penciclovir, by reacting, in the presence of a palladium catalyst and ligand; by-product inhibition; efficiency | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-04-29 | — | — | US | disclosed |
| US-6437125-B1 | REARRANGEMENT OF N-7 ALKYL GROUP TO THE N-9; PALLADIUM CATALYST AND A (DIPHENYLPHOSPHINO)ALKANE; PENCICLOVIR AND FAMCICLOVIR | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2002-08-20 | — | — | US | disclosed |
| EP-1068209-A1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR | SMITHKLINE BEECHAM PLC (GB) | 2001-01-17 | — | — | EP | disclosed |
| EP-1068210-A2 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051604-A2 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051603-A1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR | SMITHKLINE BEECHAM PLC (GB) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130512-A1 | Process for the production of purine derivatives and intermediates therefor | TYMP, DPYD, PNP | HSP90AB1 4738/4885HSP90AA1 4716/4885HSP90B1 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.